System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 8 citations

PubMed: 31064127 DOI: 10.3390/jcm8050612

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer.

J Clin Med 8(5)

Authors: Renaud Sabatier, Emmanuelle Charafe-Jauffret, Jean-Yves Pierga, Hervé Curé, Eric Lambaudie, Dominique Genre, Gilles Houvenaeghel, Patrice Viens, Christophe Ginestier, François Bertucci, Patrick Sfumato, Jean-Marc Extra, Anthony Gonçalves

Affiliations

  • Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.
  • Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.
  • Department of Biopathology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Department of Medical Oncology, Institut Curie, Paris & St Cloud, Université Paris Descartes, 75005 Paris, France.
  • Department of Medical Oncology, Institut Jean Godinot, 51100 Reims, France.
  • Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.
  • Department of Surgical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Department of Clinical Research and Innovation, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.
  • Department of Surgical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.
  • Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.
  • Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.
  • Department of Clinical Research and Innovation, Biostatistics unit, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Aix Marseille Univ, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.

Abstract

Preclinical works have suggested cytotoxic chemotherapies may increase the number of cancer stem cells (CSC) whereas angiogenesis inhibition may decrease CSC proliferation. We developed a proof of concept clinical trial to explore bevacizumab activity on breast CSC. Breast cancer patients requiring preoperative chemotherapy were included in this open-label, randomized, prospective, multicenter phase II trial. All received FEC-docetaxel combination, and patients randomized in the experimental arm received concomitant bevacizumab. The primary endpoint was to describe ALDH1 (Aldehyde dehydrogenase 1) positive tumor cells rate before treatment and after the fourth cycle. Secondary objectives included safety, pathological complete response (pCR) rate, disease-free survival (DFS), relapse-free survival (RFS), and overall survival (OS). Seventy-five patients were included. ALDH1+ cells rate increase was below the predefined 5% threshold in both arms for the 32 patients with two time points available. Grade 3 or 4 adverse events rates were similar in both arms. A non-significant increase in pCR was observed in the bevacizumab arm (42.6% vs. 18.2%, = 0.06), but survival was not improved (OS: = 0.89; DFS: = 0.45; and RFS: = 0.68). The increase of ALDH1+ tumor cells rate after bevacizumab-based chemotherapy was less than 5%. However, as similar results were observed with chemotherapy alone, bevacizumab impact on breast CSC cells cannot be confirmed.

MeSH

Drug Therapy, Stem Cells, Breast Neoplasms, Microscopy, Electron, Scanning Transmission, Disease-Free Survival, Bevacizumab, Chemotherapy

Cited by